NCT00702494View on ClinicalTrials.gov

Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Solid Tumors
Interventions
BIOLOGICAL

TB-403

Multiple IV

Trial Locations (2)

DK-2100

Onkologisk Klinik 5072 Finsencentret Rigshospitalet, Copenhagen

DK-2730

Onkologisk Afdeling 54B1 Herlev Hospital, Herlev

Sponsors

Collaborators (1)

Oxurion
All Listed Sponsors
collaborator

Oxurion

INDUSTRY

lead

BioInvent International AB

INDUSTRY